An update on the mechanisms of action of the peroxisome proliferator-activated receptors (PPARs) and their roles in inflammation and cancer.
about
Peroxisome proliferator-activated receptors (PPARs) and ovarian function--implications for regulating steroidogenesis, differentiation, and tissue remodeling.Advances in understanding the regulation of apoptosis and mitosis by peroxisome-proliferator activated receptors in pre-clinical models: relevance for human health and diseaseSuppression of colitis-related mouse colon carcinogenesis by a COX-2 inhibitor and PPAR ligandsThe potential for chemical mixtures from the environment to enable the cancer hallmark of sustained proliferative signallingThe non-genomic crosstalk between PPAR-gamma ligands and ERK1/2 in cancer cell linesPeroxisome proliferator-activated receptor gamma ligand-induced growth inhibition of human hepatocellular carcinomaActivation of Penile Proadipogenic Peroxisome Proliferator-Activated Receptor gamma with an Estrogen: Interaction with Estrogen Receptor Alpha during Postnatal DevelopmentYY-1224, a terpene trilactone-strengthened Ginkgo biloba, attenuates neurodegenerative changes induced by β-amyloid (1-42) or double transgenic overexpression of APP and PS1 via inhibition of cyclooxygenase-2.Pharmacological peroxisome proliferator-activated receptorgamma ligands: emerging clinical indications beyond diabetes.Therapeutic Implications of PPARgamma in Human Osteosarcoma.Anticancer Role of PPARgamma Agonists in Hematological Malignancies Found in the Vasculature, Marrow, and Eyes.Peroxisome proliferator-activated receptor-gamma: a versatile metabolic regulator.Lipid-lowering drugs in lupus: an unexplored therapeutic intervention.Peroxisome proliferator-activated receptor gamma agonists: potential use for treating chronic inflammatory diseases.Targeting PPARγ Signaling Cascade for the Prevention and Treatment of Prostate Cancer.Autonomous inhibition of apoptosis correlates with responsiveness of colon carcinoma cell lines to ciglitazone.Peroxisome proliferator-activated receptor-gamma: therapeutic target for diseases beyond diabetes: quo vadis?Peroxisome proliferator-activated receptor-γ regulates inflammation and renin-angiotensin system activity in the hypothalamic paraventricular nucleus and ameliorates peripheral manifestations of heart failure.Stress- (and diet-) related regulation of hepatic nuclear receptors and its relevance for ABC-transporter functions.Attenuation of colon inflammation through activators of the retinoid X receptor (RXR)/peroxisome proliferator-activated receptor gamma (PPARgamma) heterodimer. A basis for new therapeutic strategies.PPARgamma Agonists: Potential as Therapeutics for Neovascular RetinopathiesA Role for PPARgamma in the Regulation of Cytokines in Immune Cells and Cancer.Nuclear Receptor Cofactors in PPARgamma-Mediated Adipogenesis and Adipocyte Energy Metabolism.Present concepts and future outlook: function of peroxisome proliferator-activated receptors (PPARs) for pathogenesis, progression, and therapy of cancer.Thiazolidinediones in dermatology.Peroxisome proliferator-activated receptor gamma as a novel therapeutic target in asthma.Role of peroxisome proliferator-activated receptor alpha in the control of cyclooxygenase 2 and vascular endothelial growth factor: involvement in tumor growth.The molecular mechanisms of action of PPAR-γ agonists in the treatment of corneal alkali burns (Review)15-PGJ2, but not thiazolidinediones, inhibits cell growth, induces apoptosis, and causes downregulation of Stat3 in human oral SCCa cells.PPAR-gamma Thiazolidinedione Agonists and Immunotherapy in the Treatment of Brain Tumors.Peroxisome-proliferator-activated receptor alpha agonists inhibit cyclo-oxygenase 2 and vascular endothelial growth factor transcriptional activation in human colorectal carcinoma cells via inhibition of activator protein-1.Peroxisome proliferator-activated receptor gamma activation modulates cyclin D1 transcription via beta-catenin-independent and cAMP-response element-binding protein-dependent pathways in mouse hepatocytes.Activators of peroxisome proliferator-activated receptor-alpha partially inhibit mouse skin tumor promotion.Association of peroxisome proliferator-activated receptor-gamma gene polymorphisms and gene-gene interaction with asthma risk in a Chinese adults population.A specific peroxisome proliferator-activated receptor-gamma (PPAR-gamma) ligand, pioglitazone, ameliorates gastric mucosal damage induced by ischemia and reperfusion in rats.Molecular determinants of the balance between co-repressor and co-activator recruitment to the retinoic acid receptor.HRASLS3 is a PPARgamma-selective target gene that promotes adipocyte differentiationPPARgamma-mediated antineoplastic effect of NSAID sulindac on human oral squamous carcinoma cells.Peroxisome proliferator-activated receptor gamma agonist ligands stimulate a Th2 cytokine response and prevent acute colitis.Effects of perfluorooctane sulfonate (PFOS) exposure on markers of inflammation in female B6C3F1 mice.
P2860
Q21245560-34FABBD3-8CAF-41EA-8460-886D46618F60Q24803926-49900CC4-BC80-4937-B035-743695F9A129Q24810709-366A9AA0-8167-43D5-8310-5C12B6AB49E4Q28087571-65C4EEED-EC6D-49CD-A8E6-3D8970D8D678Q28238709-A95D586F-6FA9-4DA6-9A37-2094FA874418Q28366616-D47E004C-3F1B-41AF-B2E4-D1D09A168DE7Q28580476-DAF1563E-924C-438D-B26A-F05409BF6FB5Q30847206-3E016D7B-1EC9-4D4C-94EF-144BBB2547B9Q30977623-255D4E44-FA14-400A-A1C1-AC831B95B3B5Q33674615-1420E383-CB3B-4A3D-928E-5D0D4C92C6CBQ33692555-4E82FB92-BCB4-484A-99D7-5D890DB48638Q33780711-C731BAC0-AD01-43EE-B374-6E1C9AE825A8Q34227152-1E97BBC1-FB63-4A78-9B77-9C10C1A3A66CQ34580424-9B6D32E4-4273-46F5-8395-DF4ADC610158Q34646050-37FC142B-1971-415C-A3BF-FF2B842125C9Q34680692-E8891D1E-03D7-41E6-9E6B-A2D02D624309Q35688221-4EBD3EB3-4595-43D8-BCAB-6EC1D11DF7D7Q35696867-C1768E92-10C3-4A48-8B42-D961128C8C0AQ35828054-9708715B-87CE-4047-AEE9-A0456BA42913Q36369124-BA10A624-8B15-42FB-88F3-F5CA628B9DADQ36676571-ADA73794-3E63-4713-9B1C-C5B392C0B876Q36724717-8E840F2D-92D8-4404-9DEF-04280C95622CQ36772290-487F7ED4-4F82-4F45-A9CF-2D1820BC0B4BQ36795404-51EF2C7C-412B-43F6-B5A1-F7D71E8AF34FQ36841072-9A82D19E-0566-48BD-82F3-CEA81867B0B9Q37079967-529EE077-FE48-40AA-AF05-A030358AD62FQ37231752-F1A6ADCA-0C49-4B5D-8BC1-6C9E88C6FF18Q37269942-79C4FAC6-C0E1-4697-8E77-68DBF711593AQ38292542-529295D5-64FC-4C89-B6A1-382C0C193C8AQ38620031-A1BA3F3E-66EC-4D44-8504-4E748CE807B4Q40341163-BFD147D9-692D-4C3E-BB9B-D9D5D36D3B9BQ40592239-4A312ECD-16CB-4500-B071-96B9C6198555Q40838634-0856A148-DB2D-40ED-9DA2-99250B8E5E1CQ41563936-BB406366-0DC5-445C-BD44-525A3BDBBCD8Q42439583-F10DE4ED-25E8-4E9E-8BF2-EF2776178F15Q42446089-63B409EA-FD9F-4556-8FA5-7C38DCE5802CQ42810116-2B9BE8AC-2649-4D2A-99D9-50DDE19CB6A9Q43956027-AEFB3BFB-5D8E-43E5-81CA-9F77DA1AE3A7Q44247093-947BC391-3674-46D8-B137-C1E5E903A4F1Q44249631-A45F5B79-DF69-47DD-82E5-42CEF7D29E2E
P2860
An update on the mechanisms of action of the peroxisome proliferator-activated receptors (PPARs) and their roles in inflammation and cancer.
description
1999 nî lūn-bûn
@nan
1999 թուականի Յունիսին հրատարակուած գիտական յօդուած
@hyw
1999 թվականի հունիսին հրատարակված գիտական հոդված
@hy
1999年の論文
@ja
1999年論文
@yue
1999年論文
@zh-hant
1999年論文
@zh-hk
1999年論文
@zh-mo
1999年論文
@zh-tw
1999年论文
@wuu
name
An update on the mechanisms of ...... es in inflammation and cancer.
@ast
An update on the mechanisms of ...... es in inflammation and cancer.
@en
type
label
An update on the mechanisms of ...... es in inflammation and cancer.
@ast
An update on the mechanisms of ...... es in inflammation and cancer.
@en
prefLabel
An update on the mechanisms of ...... es in inflammation and cancer.
@ast
An update on the mechanisms of ...... es in inflammation and cancer.
@en
P356
P1476
An update on the mechanisms of ...... es in inflammation and cancer.
@en
P2093
P2888
P304
P356
10.1007/S000180050345
P50
P577
1999-06-01T00:00:00Z